News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Enigma Diagnostics to Feature the Enigma ML at the American Association for Clinical Chemistry Expo in Anaheim, California 25 to 29 July 2010



7/21/2010 12:05:18 PM

OXFORD, England and SAN DIEGO, July 21 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today that it is featuring the Enigma ML (Mini-Laboratory) at this year's American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo, July 25-29 at the Anaheim Convention Center in Anaheim, California. Senior management of Enigma Diagnostics Limited will be available to provide information about the Enigma ML and will be located in the point-of-care section at Booth #1530.

Enigma Diagnostics Limited will showcase its fully automated real-time PCR (Polymerase Chain Reaction) system, the Enigma ML, which enables fast and accurate 'test and treat' molecular diagnostics at point-of-care with minimal operator training. This simple-to-use portable and self-contained instrument will deliver raw sample to result in less than 60 minutes, providing laboratory standard results in real time enabling users to immediately determine the correct treatment for patients. The Enigma ML is currently being developed to detect and identify infectious organisms, such as bacteria and viruses, in clinical and biological samples.

For further information about the 2010 AACC Annual Meeting, please visit the event website at http://www.aacc.org/events/2010am/pages/default.aspx.

About Enigma Diagnostics Limited

Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings. Enigma's innovative and proprietary technologies combine the speed and sensitivity of real-time PCR (Polymerase Chain Reaction) with the simplicity needed for decentralised and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialisation strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.

For more information visit www.enigmadiagnostics.com.

Contact:

Josephine Deniau

Communications Manager

josephine.deniau@enigmadiagnostics.com

971 (0)4 446 2948



SOURCE Enigma Diagnostics Limited


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES